Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Gail J. Roboz discusses the role of minimal residual disease (MRD) testing in the treatment of acute myeloid leukemia (AML). © 2019 Imedex, an HMP Company
MRD in Acute Myeloid Leukemia
